newsfilter
← Latest News
GlobeNewswire·

Akouos Reports Second Quarter 2022 Financial Results and Provides Business Highlights

Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expres